This research is being done to see how bariatric surgery and weight loss affect levels of oral anticoagulant (blood thinner). To do this, we will study how the dose of anticoagulant is absorbed prior to surgery. Then we will investigate if the dose should be different from the amount given before surgery. Because the digestive tract is changed with bariatric surgery, it is possible that the absorption of oral anticoagulants is also changed. We will study how the same dose of anticoagulant is absorbed after surgery in comparison to before surgery.
The oral anticoagulant used in this study is called apixaban (Eliquis™). Apixaban is approved by the Food and Drug Administration (FDA) for the treatment and prevention of blood clots. The dose of apixaban you will receive on each dosing day (5 mg) is the same as the dose given for treatment of blood clots in the legs or the lungs, but more than the dose given to prevent blood clots (2.5 mg).
|Recruitment Contact Name:||Robert Juaro, RN|
Location of Study Visits:
Study will provide compensation: Yes